Bloomberg Intelligence SpaceX Said to File Confidentially for IPO Before AI Rivals
Apr 1, 2026
Hannah Levitt, senior finance reporter covering JPMorgan’s American Dream Initiative and banking trends. Diana Gomes, senior equity analyst on the Unilever-McCormick foods tie-up and its strategic trade-offs. Mandeep Singh, global tech research head on NVIDIA, Marvell and AI chip ecosystem dynamics. Sam Fezzelli, pharma research director on M&A moves and pipeline strategies. They discuss deal rationale, AI chip bottlenecks, bank lending programs, and pharma consolidation.
AI Snips
Chapters
Transcript
Episode notes
Unilever McCormick Deal Increases Execution Risk
- Unilever and McCormick combine to pair Unilever's iconic food brands with McCormick's natural-ingredient expertise for scale in protein-rich and emerging markets.
- Diana Gomes warns execution risk is high because McCormick will absorb many assets and must lift growth to 3–5% from ~2%.
Stock Heavy Terms Fuel Investor Skepticism
- Investors reacted to deal terms because the foods split is stock-heavy with only about $16 billion cash for a ~$22 billion revenue business.
- Diana Gomes says the structure means Unilever won't get a clear-cut exit and heightened uncertainty amplifies skepticism.
Big Pharma Buys Are Small Bets For Lilly
- Eli Lilly's $6–7.8 billion acquisitions are small relative to its scale but strategically pad its neuroscience pipeline.
- Sam Fezzelli notes consensus models expect the acquired assets to be a ~$2 billion business by 2033–34, a modest add to Lilly's revenue trajectory.